Modeling of degradation and drug release from a biodegradable stent coating.
Biodegradable polymeric coatings on cardiovascular stents can be used for local delivery of therapeutic agents to diseased coronary arteries after stenting procedures. This can minimize the occurrence of clinically adverse events such as restenosis after stent implantation. A validated mathematical model can be a very important tool in the design and development of such coatings for drug delivery. The model should incorporate the important physicochemical processes responsible for the polymer degradation and drug release. Such a model can be used to study the effect of different coating parameters and configurations on the degradation and the release of the drug from the coating. In this paper, a simultaneous transport-reaction model predicting the degradation and release of the drug Everolimus from a polylactic acid (PLA) based stent coating is presented. The model has been validated using in vitro testing data and was further used to evaluate the influence of various parameters such as partitioning coefficient of water, autocatalytic effect of the lactic acid and structural change of the matrix, on the PLA degradation and drug release. The model can be used as a tool for predicting drug delivery from other coating configurations designed using the same polymer-drug combination. In addition, this modeling methodology has broader applications and can be used to develop mathematical models for predicting the degradation and drug release kinetics for other polymeric drug delivery systems.
Prabhu
Santosh
S
Cardiac Therapies, Abbott Vascular, Santa Clara, California 95054, USA. sprabhu@guidant.com
Hossainy
Syed
S
D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000627:therapeutic use; D008962:Models, Theoretical; D011091:Polyesters; D011108:Polymers / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D015607:Stents
D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D000068338:Everolimus; D020123:Sirolimus